David Grimwade

31.8k citations
152 papers · 15.6k indexed · 7 hit papers · h-index 50

Impact in

  • Hematology top 0.01%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 0.1%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Acute Myeloid Leukemia Research 118
    • Chronic Myeloid Leukemia Treatments 19
    • Retinoids in leukemia and cellular processes 87
    • Protein Degradation and Inhibitors 16
    • Advanced biosensing and bioanalysis techniques 15

David Grimwade

150 papers receiving 15.2k citations

Hit Papers

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial 2015 · 346 citations
346199820262007201650010001.5k2.0k

Peers

David Grimwade
Comparison fields: 5 of 124
  • Hematology 12.7k
  • Genetics 3.0k
  • Public Health, Environmental and Occupational Health 4.5k
  • Molecular Biology 8.4k
  • Biochemistry 619
Replace Francesco Lo‐Coco with:
Francesco Lo‐Coco Italy
Elisabeth Paietta United States
Sylvie Castaigné France
Nigel H. Russell United Kingdom
Eva Hellström‐Lindberg Sweden
Gautam Borthakur United States
Alessandra Ferrajoli United States
Uwe Platzbecker Germany
C. Sultan France
Tapan M. Kadia United States
David Grimwade relative to Francesco Lo‐Coco Italy Francesco Lo‐Coco's profile →
Citations per field
00.5×1.5×
Francesco Lo‐Coco · 1×
Citations per year

Countries citing papers authored by David Grimwade

Since Specialization
Citations

This map shows the geographic impact of David Grimwade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Grimwade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Grimwade more than expected).

Fields of papers citing papers by David Grimwade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Grimwade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Grimwade. The network helps show where David Grimwade may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Grimwade, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Grimwade Line = papers co-authored together David Grimwade links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20213
2 20172
3 2015292
4
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Hit paper breakdown →
2015346
5
COMBINED ANALYSES OF ROS, CELL CYCLE AND IMMUNOPHENOTYPE SHOWS THAT NORMAL HEMATOPOIETIC PROGENITOR SUBSETS HAVE A DIFFERENTIAL ROS PROFILE THAT IS LOST IN ACUTE MYELOID LEUKEMIA
20131
6
Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials
201029
7
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hit paper breakdown →
20092350
8
REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS
20095
9 20063
10
The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia.
20033
11
Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.
20033
12
Refinement of cytogenetic classification in AML: determination of prognostic significance of rare recurring chromosomal abnormalities amongst patients entered into the UK MRC AML 10 & 12 trials.
20023
13
Mutation analysis of the Fanconi Anaemia group A, C, E, F and G genes in sporadic acute myeloid leukaemia
20010
14
Rexinoid therapy bypasses the differentiation block associated with acute promyelocytic leukemia harboring the PLZF/RAR alpha rearrangement.
20013
15
Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies"
200030
16
Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
19998
17
The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
19995
18
Morphological presentation of acute promyelocytic leukemia (APL) lacking the classical t(15;17) with special reference to a series of 9 cases with t(11;17)
19983
19
The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial
19982
20
Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
19966

About David Grimwade

David Grimwade is a scholar working on Hematology, Molecular Biology, Public Health, Environmental and Occupational Health, Biochemistry and Genetics, having authored 152 papers that have together received 15.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (118 papers), Retinoids in leukemia and cellular processes (87 papers), Acute Lymphoblastic Leukemia research (47 papers), Chronic Myeloid Leukemia Treatments (19 papers), Protein Degradation and Inhibitors (16 papers), Advanced biosensing and bioanalysis techniques (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Drug-Induced Ocular Toxicity (8 papers). The work is most often cited by research in Hematology (12.7k citations), Genetics (3.0k citations), Public Health, Environmental and Occupational Health (4.5k citations), Molecular Biology (8.4k citations) and Biochemistry (619 citations). David Grimwade has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Alan K. Burnett, Keith Wheatley, Robert K. Hills, Christine J. Harrison, Helen M. Walker, Anthony P. Goldstone, Ian Hann, Anthony H. Goldstone, Sylvie Freeman and Fiona Oliver. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Genes Chromosomes and Cancer and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026